Skip to content

Medpace

US · MEDP #1015 by market cap Listed 2016
610.54 -23.44 -3.70%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 634.31 +0.05%
After-hours 605.49 -0.83%
Overnight 665.73 +5.01%
692.68428.00610.542026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on MEDP?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +1.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has fallen to 4.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall B+
ValuationGrowthProfitMomentumHealthAnalyst
Valuation D+

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 33.9x Better than 18%
Forward P/E 31.6x Better than 17%
Price / Sales 6.0x Better than 18%
P/E vs own 5-yr range 60th pctl Better than 48%
Growth A

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 20.1% Better than 82%
Net income CAGR (3Y) 22.5% Better than 74%
Free cash flow CAGR (3Y) 24.8% Better than 69%
Profitability A-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 30.1% Better than 32%
Operating margin 21.1% Better than 79%
Net margin 17.8% Better than 76%
Return on equity 70.2% Better than 96%
Return on invested capital 59.2% Better than 99%
Momentum A-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -1.6% Better than 70%
6-month return 41.1% Better than 93%
12-month return (ex latest month) 13.1% Better than 51%
Distance below 52-week high 12.0% Better than 78%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 0.7x Better than 9%
Debt to assets 5.8% Better than 78%
Interest coverage 80.6x Better than 92%
Free cash flow / net income 151.1% Better than 66%
Analyst View D+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 37.5% Better than 20%
Upside to average target 13.2% Better than 19%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -6.64%
1M -1.91%
3M -0.34%
6M +44.72%
YTD +8.70%
1Y +4.16%
3Y +121.23%
5Y +168.95%

Key statistics

Price & volume

Prev close
633.98
Open
632.09
Day range
606.73 - 633.87
Avg price
616.08
Volume
236.77K
Turnover
145.87M
Amplitude
4.28%
52-week range
373.00 - 693.97

Valuation

P/E
39.96
P/E (TTM)
33.90
P/B
29.20
EPS
15.28
Net profit
427.41M
Net assets
584.94M

Share structure

Market cap
17.08B
Float cap
13.88B
Shares out
27.97M
Float shares
22.73M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2016-08-11
52-week range 74% of range
373.00 693.97

12.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+15.75M net over the window

Short interest

Shares short
1.38M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Medpace (MEDP)?

Medpace last traded at 610.54. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Medpace's market cap?

About 17.08B.

What is the P/E ratio of Medpace?

The trailing twelve-month P/E is 33.90, above its own 5-year average of 32.65 — in the middle of its historical range (60.48% percentile). See the Valuation tab for the full history.

Does Medpace pay a dividend?

Medpace does not currently pay a regular dividend.

Is Medpace a buy according to analysts?

The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 691.29, which implies 13.2% upside from the current price. This is not investment advice.

What is Medpace's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Medpace a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Medpace discussion 0 comments

Add a comment